Sprycel® (dasatinib) – Expanded indication
December 21, 2018 - The FDA approved Bristol-Myers Squibb’s Sprycel (dasatinib) tablets, for the treatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
Top